The Medical Letter on Drugs and Therapeutics
Omalizumab (Xolair) for Chronic Urticaria
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Omalizumab (Xolair) is a recombinant humanized monoclonal anti-IgE antibody currently approved by the FDA for treatment of moderate to severe persistent allergic asthma.1 It has been used off-label for treatment of allergic rhinitis and food allergies. Recently the results of a phase III clinical trial indicated that omalizumab may be effective in treating chronic urticaria as well.2

STANDARD TREATMENT — Second-generation H1-antihistamines are the current standard of care for chronic urticaria (hives that persist for ≥6 weeks).3,4 However, many patients do not respond to usual doses and some do not respond to up-dosing (off-label), even at 4 times the usual dose.5,6 Second-line agents include first-generation ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Omalizumab (Xolair) for Chronic Urticaria
Article code: 1417b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian